Merck's Cholesterol Drug Excels in Phase 3 Trials
TL;DR Summary
Merck announced positive topline results from two Phase 3 trials of enlicitide decanoate, an oral PCSK9 inhibitor, showing significant LDL-C reductions in adults with hyperlipidemia, potentially making it the first oral PCSK9 inhibitor if approved.
- Merck Announces Positive Topline Results From the First Two Phase 3 CORALreef Trials Evaluating Enlicitide Decanoate for the Treatment of Adults With Hyperlipidemia Merck.com
- Merck & Co.'s oral PCSK9 inhibitor succeeds in dual Phase III trials FirstWord Pharma
- Merck's leader in oral PCSK9 inhibitor race reduces cholesterol in pair of phase 3 trials Fierce Biotech
- Merck's cholesterol drug meets main goal in two studies Reuters
- Merck's potential cholesterol pill succeeds in late-stage studies Business Standard
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
7 min
vs 8 min read
Condensed
98%
1,492 → 35 words
Want the full story? Read the original article
Read on Merck.com